🤝 Schemes & WelfareMAINS · GS2.13 · GS2.10

8th Janaushadhi Diwas marks generic-medicine push

The annual day for the scheme that supplies low-cost generic medicines through Jan Aushadhi Kendras, closing a week-long Janaushadhi Saptah.

What happened

The 8th Janaushadhi Diwas was observed on 7 March 2026, marking the culmination of the week-long Janaushadhi Saptah 2026 (1–7 March), organised by the Pharmaceuticals & Medical Devices Bureau of India (PMBI) under the Department of Pharmaceuticals.
Events ran at 25 locations nationally; the central function was held at Bharat Mandapam, New Delhi, with Union Minister for Chemicals and Fertilizers Shri J. P. Nadda as Chief Guest and MoS Smt. Anupriya Patel as Guest of Honour.
Awards were presented to 13 Jan Aushadhi Kendras, including units from Tamil Nadu, West Bengal and Delhi; Kendra owners were felicitated as the public face of the network.
The minister flagged three focus areas: quality and awareness of generic medicines, regular supply and distribution, and sustainable margins for Kendra operators.
MoS Anupriya Patel noted that of 18,000+ Kendras, more than 8,000 are run by women, framing the network as a livelihood and women-entrepreneurship channel, not only a medicine-supply one.
The Saptah included over 250 health check-up camps (1–5 March) and Pad Yatras at 30+ locations on the sixth day; the scheme was described as having grown into an andolan (people's movement) feeding the Viksit Bharat 2047 goal.

Background & context

Janaushadhi Diwas is the anniversary observance of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — literally the "Prime Minister's Indian People's-Medicine Scheme." It is a central-sector campaign of the Department of Pharmaceuticals, which sits within the Ministry of Chemicals and Fertilizers. The scheme's purpose is narrow and concrete: to make quality generic medicines available at affordable prices to all, through a chain of dedicated outlets branded Jan Aushadhi Kendras (JAKs), formally the Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs).

The programme has a layered lineage that aspirants frequently confuse. The original Jan Aushadhi Scheme was launched in 2008. It was relaunched and re-energised as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, and the implementing agency — first incorporated as the Bureau of Pharma PSUs of India (BPPI) — was renamed the Pharmaceuticals & Medical Devices Bureau of India (PMBI). PMBI is the body that procures medicines, runs the supply chain, and certifies and supports the Kendras on the ground; the Department of Pharmaceuticals owns the policy and the budget. The annual Janaushadhi Diwas is held on 7 March, and the week leading up to it is observed as Janaushadhi Saptah — a recurring revision peg, because the date and the entity reappear in current-affairs sets each year.

The economic logic rests on the difference between branded and generic medicines. A generic drug contains the same active pharmaceutical ingredient, in the same dose and form, as a branded original whose patent has expired; it is therapeutically equivalent but is sold under its chemical name rather than a marketing brand. Because the manufacturer carries no large promotion or branding cost, the generic can be priced far lower. PMBJP institutionalises this gap: the medicines at a Jan Aushadhi Kendra are generally priced 50–80% below their branded equivalents, which is the single number most worth carrying from this release. India is, in fact, often called the "pharmacy of the world" for its large generic-drug manufacturing base — PMBJP turns that manufacturing strength inward, putting domestically-made generics within reach of the domestic patient rather than leaving the home market to high-priced brands.

It helps to place PMBJP within the wider affordable-medicine ecosystem the government runs, because the names are easy to mix up in a "match the pairs" question. The National Pharmaceutical Pricing Authority (NPPA), also under the Department of Pharmaceuticals, caps the prices of essential drugs through the Drug Price Control Order (DPCO) and the National List of Essential Medicines (NLEM) — that is price regulation of the whole market. AMRIT (Affordable Medicines and Reliable Implants for Treatment) pharmacies, run with HLL Lifecare in major hospitals, discount high-cost cancer and cardiac drugs and implants. Ayushman Bharat – PM-JAY provides hospitalisation insurance cover. PMBJP is the retail generic-outlet arm of this family: it does not regulate prices market-wide, it does not insure, and it is not hospital-bound — it sells low-cost generics across the counter to walk-in citizens. Holding these four apart is exactly the kind of distinction Prelims tests.

For Prelims

Full name: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — the Jan Aushadhi programme; the outlets are Jan Aushadhi Kendras (JAKs / PMBJKs).
Nodal chain: Department of Pharmaceuticals → Ministry of Chemicals and Fertilizers; implemented by PMBI (Pharmaceuticals & Medical Devices Bureau of India), earlier the BPPI.
Lineage: original Jan Aushadhi Scheme launched 2008; relaunched/expanded as PMBJP; a central-sector initiative (fully Union-funded, not centrally-sponsored / not cost-shared with States).
Price advantage: medicines generally 50–80% cheaper than branded equivalents — the defining metric.
Network size: 18,000+ Kendras operational; declared target 25,000 Kendras (by around March 2027).
Women-led: over 8,000 of the 18,000+ Kendras are operated by women.
Annual peg: Janaushadhi Diwas = 7 March; the run-up week is Janaushadhi Saptah (1–7 March in 2026).
Citizen tool: the 'Janaushadhi Sugam' mobile app locates the nearest Kendra, checks product availability and compares generic-versus-branded prices.
Product basket: the Kendras stock a wide range of medicines plus surgical and nutraceutical products across major therapeutic groups, all under generic names.

What it is NOT: PMBJP is not a free-medicine or insurance scheme — it sells generics at low cost, it does not give them away, and it is distinct from Ayushman Bharat – PM-JAY (health-insurance cover) and from the AMRIT pharmacies (which discount cancer/cardiac drugs at hospitals). It is also not centrally-sponsored; it is a central-sector scheme run directly by the Centre. And the medicines are generic, not counterfeit or substandard — they are quality-tested drugs sold by chemical name rather than a brand.

For UPSC: PMBJP supplies generic medicines 50–80% cheaper via 18,000+ Jan Aushadhi Kendras (target 25,000 by March 2027), implemented by PMBI under the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers); Janaushadhi Diwas falls on 7 March.

Why it matters

India carries one of the world's highest shares of out-of-pocket health expenditure, and medicines are the largest single component of that household spend. When a patient on a chronic regimen — diabetes, hypertension, cardiac care — pays brand prices month after month, the drug bill alone can push a family below the poverty line. PMBJP attacks exactly this pressure point: by making the generic version available at a fraction of the branded cost through a physical outlet in the patient's own town, it lowers the recurring medicine bill and reduces the catastrophic-health-spending risk that insurance alone does not solve.

The release adds a second, quieter dimension worth carrying for answers: the Kendra network doubles as a self-employment and women-entrepreneurship platform. With more than 8,000 of the outlets run by women, the scheme converts a public-health delivery channel into a small-business livelihood, especially in semi-urban and rural areas. That is why the minister framed the focus on sustainable margins for operators — the network only survives if running a Kendra remains commercially viable, so affordability for the patient must be balanced against a workable return for the entrepreneur. This tension — low ceiling prices for patients versus thin operator margins — is a genuine policy problem the scheme itself acknowledges, and it is the kind of admitted gap that makes good Mains material.

There is also a public-health behaviour change embedded in the scheme that the framing of "quality and awareness" points to. Many patients and even prescribers default to branded drugs out of habit or a perception that a brand signals reliability; a generic carrying only its chemical name can feel unfamiliar by comparison. By building a visible, dedicated retail chain, running awareness drives during Janaushadhi Saptah, and offering the Janaushadhi Sugam app so a citizen can verify availability and compare prices before walking in, the programme works to normalise the generic choice. The 250-plus health check-up camps and the Pad Yatras during the Saptah are part of that same demand-side effort: they push the scheme outward as a movement rather than waiting for footfall. Reading the scheme this way — supply chain plus price advantage plus a deliberate trust-and-awareness campaign — is what lifts it from a fact to a usable argument about how welfare delivery actually reaches people.

For Mains

Anchor

PMBJP can anchor an answer on improving healthcare access and affordability: a state-built supply chain that uses the generics-versus-brand price gap to cut out-of-pocket medicine spending (GS2.13).

Data

Concrete figures to substantiate any health-financing or welfare-delivery answer: 18,000+ Kendras, target 25,000, prices 50–80% lower, 8,000+ women-run outlets.

Exemplification

A clean example of a government intervention on a market failure (information asymmetry and brand premium in pharma) and of convergence between welfare and women's livelihoods (GS2.10).

Problematisation

The scheme's own balancing act — affordable ceiling prices versus viable operator margins, plus questions of quality assurance and consistent supply — supplies the critique side of an answer.

Way-forward

Use the stated focus areas — quality and awareness, reliable supply, sustainable margins — as a ready-made way-forward on expanding affordable-medicine access toward the 25,000-Kendra goal.

Deploys into: health-sector reach and out-of-pocket spending · government policies and interventions for vulnerable sections · welfare-plus-livelihood convergence and women's economic participation.

Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals) · 2026-03-07 · PRID 2236418 · PIB source ↗